Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Sarcoidosis Workup

  • Author: Nader Kamangar, MD, FACP, FCCP, FCCM; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
 
Updated: May 31, 2016
 

Laboratory Studies

Serum markers such as serum amyloid A (SAA), soluble interleukin-2 receptor (sIL-2R), lysozyme, angiotensin-converting enzyme (ACE), and the glycoprotein KL-6 have been reported to be markers of sarcoidosis.[42]

Hypercalcemia or hypercalciuria may occur (noncaseating granulomas [NCGs] secrete 1,25 vitamin D). Hypercalcemia is seen in about 10-13% of patients, whereas hypercalciuria is 3 times more common.

Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. In one study, serum 1, 25-dihydroxyvitamin D levels were associated with patients requiring repeated regimens of systemic immunosuppressive therapy or longer than 1 year of therapy. The majority (71%) of the patients with levels higher than 51 pg/mL required long-term immunosuppressive therapy.[43]

An elevated alkaline phosphatase level could suggest hepatic involvement. One study has shown that the severity of liver function test abnormalities is significantly related with the degree of fibrosis and extensiveness of the granulomatous inflammation in sarcoidosis.[44]

ACE levels may be elevated. NCGs secrete ACE, which may function as a cytokine. Serum ACE levels are elevated in 60% of patients at the time of diagnosis. Serum ACE levels may correlate with total body granuloma load. Levels may be increased in fluid from bronchoalveolar lavage or in cerebrospinal fluid. Sensitivity and specificity as a diagnostic test is limited (60% and 70%, respectively). There is no clear prognostic value. Serum ACE levels may decline in response to therapy. Decisions on treatment should not be based on the ACE level alone.

Next

Imaging Studies

A chest radiograph is central to evaluation.

Air trapping is a common feature in sarcoidosis that can be supported with imaging studies and correlates with evidence of small airways disease on pulmonary function testing.[45]

Routine chest CT scanning adds little to diagnosis. High-resolution CT (HRCT) scanning of the chest may identify active alveolitis or fibrosis and correlates with yield of biopsy.

Some studies have suggested that whole body F(18)-fluorodeoxyglucose positron emission tomography (FDG-PET) scanning appears to be of additional value to assess inflammatory activity in patients with persistent symptoms in the absence of signs of serological inflammatory activity and to detect extrathoracic lesions.[46] Whole-body FDG-PET scanning is of value in identifying occult and reversible granulomas in patients with sarcoidosis.[47]

Prior to the ease and availability of bronchoscopy, gallium scanning was occasionally used as a diagnostic test. It may still be helpful in a subset of patients in whom the clinical picture remains confusing despite histologic evidence of noncaseating granulomas (NCGs) (eg, differentiating chronic hypersensitivity pneumonitis from sarcoidosis).

Previous
Next

Other Tests

Pulmonary function tests and a carbon monoxide diffusion capacity test of the lungs for carbon monoxide (DLCO) may be performed. They are used routinely in evaluation and follow-up. The most common abnormality is an isolated decrease in DLCO. A restrictive pattern is seen in patients with more advanced pulmonary disease. Approximately 15-20% of patients have obstruction.

Patients with DLCO of less than 60% predicted and oxygen desaturation of less than 90% on the 6-minute walk test have a high likelihood of pulmonary hypertension and should undergo further evaluation for the presence of this disorder.[48] In one study, patients with a saturation of less than 90% during a 6-minute walk test were 12 times more likely to have pulmonary hypertension.[48]

Cardiopulmonary exercise testing is a sensitive test for identifying and quantifying the extent of pulmonary involvement. Cardiopulmonary exercise testing also may suggest cardiac involvement that otherwise is not evident.

Attenuated heart rate recovery after exercise is thought to be a marker of reduced parasympathetic activity. Impaired heart rate recovery during the first minute following exercise has been shown to be an independent predictor for cardiovascular and all-cause mortality.[1, 49] Considering its prognostic significance, the heart rate recovery index may have clinical use in identifying patients with sarcoidosis who are at high risk for ventricular arrhythmias and sudden death.[2]

In accordance with the position statement of the American Thoracic Society, all patients should have an annual ECG. If patients report palpitations, this should prompt a thorough evaluation.

Previous
Next

Procedures

Diagnosis requires biopsy in most cases. If therapy is to be given for sarcoidosis, tissue confirmation is essential. Watchful waiting is indicated only for patients who exhibit a classic presentation, are asymptomatic, and with whom one can ensure close follow-up.

Transbronchial biopsy via fiberoptic bronchoscopy has a high diagnostic yield. Results may be positive, even in the setting of normal chest radiography findings.

Standard transbronchial needle aspiration allows successful lymph node sampling in nearly all patients with sarcoidosis and is associated with high diagnostic yield regardless of disease stage.[50]

Endobronchial biopsy is performed during bronchoscopy and increases the yield of the procedure. In a study of 34 subjects, endobronchial biopsy findings were positive in 61.8% of patients with a yield comparable to transbronchial biopsy, which showed nonnecrotizing granulomas in 58.8% of subjects. The addition of endobronchial biopsy increased the yield of fiberoptic bronchoscopy by 20.6%.[51]

At least one study has shown that the diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration for stage I and II sarcoidosis is even higher than standard transbronchial lung biopsy.[52]

In at least one study, the CD4/CD8 ratio and tumor necrosis factor (TNF)–α levels in induced sputum correlated with those in bronchoalveolar lavage fluid (BALF) and paralleled changes with treatment. Induced sputum may therefore be a surrogate for BALF for certain markers in patients with sarcoidosis.[53] In another study, the differential cell count in BALF demonstrated a significantly lower percentage of neutrophils and a significantly higher percentage of macrophages than in induced sputum. The profiles of T-cell subsets, however, showed the same pattern in both groups. A CD4/CD8 ratio of 2.5 or greater had a sensitivity of 100% and a specificity of 81.2%, with a positive predictive value of 81.2%, to distinguish sarcoidosis from nongranulomatous interstitial lung diseases.[54]

Previous
Next

Histologic Findings

The central histologic finding is the presence of noncaseating granulomas (NCGs) with special stains negative for fungus and mycobacteria.

Previous
 
 
Contributor Information and Disclosures
Author

Nader Kamangar, MD, FACP, FCCP, FCCM Professor of Clinical Medicine, University of California, Los Angeles, David Geffen School of Medicine; Chief, Division of Pulmonary and Critical Care Medicine, Vice-Chair, Department of Medicine, Olive View-UCLA Medical Center

Nader Kamangar, MD, FACP, FCCP, FCCM is a member of the following medical societies: Academy of Persian Physicians, American Academy of Sleep Medicine, American Association for Bronchology and Interventional Pulmonology, American College of Chest Physicians, American College of Critical Care Medicine, American College of Physicians, American Lung Association, American Medical Association, American Thoracic Society, Association of Pulmonary and Critical Care Medicine Program Directors, Association of Specialty Professors, California Sleep Society, California Thoracic Society, Clerkship Directors in Internal Medicine, Society of Critical Care Medicine, Trudeau Society of Los Angeles, World Association for Bronchology and Interventional Pulmonology

Disclosure: Nothing to disclose.

Coauthor(s)

Andrew F Shorr, MD, MPH Associate Professor of Medicine, Georgetown University School of Medicine, Associate Direfctor of Pulmonary and Critical Care, Washington Hospital Center

Andrew F Shorr, MD, MPH is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Thoracic Society

Disclosure: Nothing to disclose.

Payam Rohani, MD Resident Physician, Department of Internal Medicine, Olive View-UCLA Medical Center

Payam Rohani, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Zab Mosenifar, MD, FACP, FCCP Geri and Richard Brawerman Chair in Pulmonary and Critical Care Medicine, Professor and Executive Vice Chairman, Department of Medicine, Medical Director, Women's Guild Lung Institute, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine

Zab Mosenifar, MD, FACP, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Thoracic Society

Disclosure: Nothing to disclose.

Additional Contributors

Stephen P Peters, MD, PhD, FACP, FAAAAI, FCCP, FCPP Thomas H Davis Chair in Pulmonary Medicine, Chief, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Professor of Internal Medicine, Pediatrics, and Translational Science, Associate Director, Center for Genomics and Personalized Medicine Research, Wake Forest University School of Medicine; Executive Director of the Respiratory Service Line, Wake Forest Baptist Medical Center

Stephen P Peters, MD, PhD, FACP, FAAAAI, FCCP, FCPP is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Thoracic Society, Sigma Xi

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Integrity CE, Merck<br/>Received income in an amount equal to or greater than $250 from: – Array Biopharma, AstraZeneca, Aerocrine, Airsonett AB, Boehringer-Ingelheim, Experts in Asthma, Gilead, GlaxoSmithKline, Merck, Novartis, Ono Pharmaceuticals, Pfizer, PPD Development, Quintiles, Sunovion, Saatchi & Saatichi, Targacept, TEVA, Theron.

References
  1. Arai Y, Saul JP, Albrecht P, Hartley LH, Lilly LS, Cohen RJ, et al. Modulation of cardiac autonomic activity during and immediately after exercise. Am J Physiol. 1989 Jan. 256(1 Pt 2):H132-41. [Medline].

  2. Shetler K, Marcus R, Froelicher VF, Vora S, Kalisetti D, Prakash M. Heart rate recovery: validation and methodologic issues. J Am Coll Cardiol. 2001 Dec. 38(7):1980-7. [Medline].

  3. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999 Jul. 160(1):192-7. [Medline].

  4. Zic JA, Horowitz DH, Arzubiaga C, King LE Jr. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol. 1991 Jul. 127(7):1034-40. [Medline].

  5. Demeter SL. Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest. 1988 Jul. 94(1):202-3. [Medline].

  6. Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest. 2003 Nov. 124(5):2023-6. [Medline].

  7. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999 Nov. 14(5):1117-22. [Medline].

  8. Kataria YP. Chlorambucil in sarcoidosis. Chest. 1980 Jul. 78(1):36-43. [Medline].

  9. York EL, Kovithavongs T, Man SF, Rebuck AS, Sproule BJ. Cyclosporine and chronic sarcoidosis. Chest. 1990 Oct. 98(4):1026-9. [Medline].

  10. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005 Mar. 127(3):1064-71. [Medline].

  11. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med. 2001 Jul 3. 135(1):27-31. [Medline].

  12. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest. 2002 Jul. 122(1):227-32. [Medline].

  13. Fazzi P, Manni E, Cristofani R, Cei G, Piazza S, Calabrese R, et al. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomed Pharmacother. 2012 Jun. 66(4):300-7. [Medline].

  14. Russell E, Luk F, Manocha S, Ho T, O'Connor C, Hussain H. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin Arthritis Rheum. 2013 Jan 16. [Medline].

  15. Nathan SD. Lung transplantation: disease-specific considerations for referral. Chest. 2005 Mar. 127(3):1006-16. [Medline].

  16. Ten Berge B, Kleinjan A, Muskens F, Hammad H, Hoogsteden HC, Hendriks RW, et al. Evidence for local dendritic cell activation in pulmonary sarcoidosis. Respir Res. 2012 Apr 18. 13:33. [Medline]. [Full Text].

  17. Mota PC, Morais A, Palmares C, Beltrao M, Melo N, Santos AC, et al. Diagnostic value of CD103 expression in bronchoalveolar lymphocytes in sarcoidosis. Respir Med. 2012 Jul. 106(7):1014-20. [Medline].

  18. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997 May. 155(5):1665-9. [Medline].

  19. Ogisu N, Sato S, Kawaguchi H, Sugiura Y, Mori T, Niimi T, et al. Elevated level of soluble HLA class I antigens in serum and bronchoalveolar lavage fluid in patients with sarcoidosis. Intern Med. 2001 Mar. 40(3):201-7. [Medline].

  20. Hunninghake GW, Crystal RG. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest. 1981 Jan. 67(1):86-92. [Medline].

  21. Kunitake R, Kuwano K, Yoshida K, Maeyama T, Kawasaki M, Hagimoto N, et al. KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Respiration. 2001. 68(5):488-95. [Medline].

  22. Miyoshi S, Hamada H, Kadowaki T, Hamaguchi N, Ito R, Irifune K, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest. 2010 Jun. 137(6):1391-7. [Medline].

  23. Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax. 2011 Feb. 66(2):144-50. [Medline].

  24. Cox CE, Davis-Allen A, Judson MA. Sarcoidosis. Med Clin North Am. 2005 Jul. 89(4):817-28. [Medline].

  25. Jordan HT, Stellman SD, Prezant D, Teirstein A, Osahan SS, Cone JE. Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster. J Occup Environ Med. 2011 Sep. 53(9):966-74. [Medline].

  26. Krell W, Bourbonnais JM, Kapoor R, Samavati L. Effect of smoking and gender on pulmonary function and clinical features in sarcoidosis. Lung. 2012 Oct. 190(5):529-36. [Medline].

  27. Nardi A, Brillet PY, Letoumelin P, Girard F, Brauner M, Uzunhan Y, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J. 2011 Dec. 38(6):1368-73. [Medline].

  28. Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011 Jun 1. 183(11):1524-30. [Medline].

  29. Takase H, Shimizu K, Yamada Y, Hanada A, Takahashi H, Mochizuki M. Validation of international criteria for the diagnosis of ocular sarcoidosis proposed by the first international workshop on ocular sarcoidosis. Jpn J Ophthalmol. 2010 Nov. 54(6):529-36. [Medline].

  30. Kojima K, Maruyama K, Inaba T, Nagata K, Yasuhara T, Yoneda K, et al. The CD4/CD8 ratio in vitreous fluid is of high diagnostic value in sarcoidosis. Ophthalmology. 2012 Nov. 119(11):2386-92. [Medline].

  31. Herbort CP, Rao NA, Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009 May-Jun. 17(3):160-9. [Medline].

  32. Herbort CP, Rao NA, Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009 May-Jun. 17(3):160-9. [Medline].

  33. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm. 2012 Jun. 9(6):884-91. [Medline].

  34. Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011 Apr. 16(2):140-7. [Medline].

  35. Schuller JL, Olson MD, Zipse MM, Schneider PM, Aleong RG, Wienberger HD, et al. Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol. 2011 Nov. 22(11):1243-8. [Medline].

  36. Yasutake H, Seino Y, Kashiwagi M, Honma H, Matsuzaki T, Takano T. Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol. 2005 Jul 10. 102(2):259-68. [Medline].

  37. Bihan H, Christozova V, Dumas JL, Jomaa R, Valeyre D, Tazi A, et al. Sarcoidosis: clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature. Medicine (Baltimore). 2007 Sep. 86(5):259-68. [Medline].

  38. Inui N, Murayama A, Sasaki S, Suda T, Chida K, Kato S, et al. Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med. 2001 Jun 15. 110(9):687-93. [Medline].

  39. Goracci A, Fagiolini A, Martinucci M, Calossi S, Rossi S, Santomauro T, et al. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry. 2008 Sep-Oct. 30(5):441-5. [Medline].

  40. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008 May. 133(5):1189-95. [Medline].

  41. Sverrild A, Backer V, Kyvik KO, Kaprio J, Milman N, Svendsen CB. Heredity in sarcoidosis: a registry-based twin study. Thorax. 2008 Oct. 63(10):894-6. [Medline].

  42. Miyoshi S, Hamada H, Kadowaki T, Hamaguchi N, Ito R, Irifune K, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest. 2010 Jun. 137(6):1391-7. [Medline].

  43. Kavathia D, Buckley JD, Rao D, Rybicki B, Burke R. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med. 2010 Apr. 104(4):564-70. [Medline].

  44. Cremers J, Drent M, Driessen A, Nieman F, Wijnen P, Baughman R, et al. Liver-test abnormalities in sarcoidosis. Eur J Gastroenterol Hepatol. 2012 Jan. 24(1):17-24. [Medline].

  45. Davies CW, Tasker AD, Padley SP, Davies RJ, Gleeson FV. Air trapping in sarcoidosis on computed tomography: correlation with lung function. Clin Radiol. 2000 Mar. 55(3):217-21. [Medline].

  46. Mostard RL, Voo S, van Kroonenburgh MJ, Verschakelen JA, Wijnen PA, Nelemans PJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med. 2011 Dec. 105(12):1917-24. [Medline].

  47. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007 Dec. 132(6):1949-53. [Medline].

  48. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J. 2008 Aug. 32(2):296-302. [Medline].

  49. Ardic I, Kaya MG, Yarlioglues M, Dogdu O, Buyukoglan H, Kalay N. Impaired heart rate recovery index in patients with sarcoidosis. Chest. 2011 Jan. 139(1):60-8. [Medline].

  50. Trisolini R, Tinelli C, Cancellieri A, Paioli D, Alifano M, Boaron M, et al. Transbronchial needle aspiration in sarcoidosis: yield and predictors of a positive aspirate. J Thorac Cardiovasc Surg. 2008 Apr. 135(4):837-42. [Medline].

  51. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial biopsy for sarcoidosis: a prospective study. Chest. 2001 Jul. 120(1):109-14. [Medline].

  52. Oki M, Saka H, Kitagawa C, Kogure Y, Murata N, Ichihara S, et al. Prospective study of endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes versus transbronchial lung biopsy of lung tissue for diagnosis of sarcoidosis. J Thorac Cardiovasc Surg. 2012 Jun. 143(6):1324-9. [Medline].

  53. Moodley YP, Dorasamy T, Venketasamy S, Naicker V, Lalloo UG. Correlation of CD4:CD8 ratio and tumour necrosis factor (TNF)alpha levels in induced sputum with bronchoalveolar lavage fluid in pulmonary sarcoidosis. Thorax. 2000 Aug. 55(8):696-9. [Medline]. [Full Text].

  54. Fireman E, Topilsky I, Greif J, Lerman Y, Schwarz Y, Man A, et al. Induced sputum compared to bronchoalveolar lavage for evaluating patients with sarcoidosis and non-granulomatous interstitial lung disease. Respir Med. 1999 Nov. 93(11):827-34. [Medline].

  55. McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci. 2010 Jan. 339(1):1-4. [Medline].

  56. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002 Jan. 121(1):24-31. [Medline].

  57. Baughman RP, Barney JB, O'Hare L, Lower EE. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med. 2016 Jan. 110:66-72. [Medline].

  58. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995 Apr 24. 155(8):846-51. [Medline].

  59. Callejas-Rubio JL, Lopez-Perez L, Ortego-Centeno N. Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Ther Clin Risk Manag. 2008 Dec. 4(6):1305-13. [Medline]. [Full Text].

  60. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012 May. 250(5):713-20. [Medline]. [Full Text].

  61. Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B. Effect of the TNF-a inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J. 2012 Oct. 6(4):238-47. [Medline].

  62. Arcasoy SM, Christie JD, Pochettino A, Rosengard BR, Blumenthal NP, Bavaria JE, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest. 2001 Sep. 120(3):873-80. [Medline].

  63. Ramos-Casals M, Mana J, Nardi N, Brito-Zeron P, Xaubet A, Sanchez-Tapias JM, et al. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore). 2005 Mar. 84(2):69-80. [Medline].

 
Previous
Next
 
Stage I sarcoidosis.
Stage II sarcoidosis.
Stage III sarcoidosis.
Table 1. Prognosis
Stage Remission (%) Asymptomatic at 5 y (%) Chest Radiograph Clearing (%) Mortality (%)
Stage I 60-90 95 54 0
Stage II 40-70 58 31 11
Stage III 10-20 25 10 18
Stage IV 0 N/A 0 N/A
Table 2. Results of Multicenter Trial Sponsored by the British Thoracic Society
Characteristics Group La Group Sb P
Dyspnea score (range 1-4) 0.24 0.47 NS
Fibrosis score (range 0-16) 0.83 1.47 NS
FEV1c (% predicted) 95.9 86.9 0.05
VCd (% predicted) 99.8 90.8 0.02
DLCOe (% predicted) 84.3 77.7 NS
Weight gain (kg) +3.26 +0.99 0.02
a Long-term steroids.



b Short bursts of steroids.



c Forced expiratory volume in 1 second.



d Ventilatory capacity.



e Diffusing capacity of lung for carbon monoxide.



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.